The androgen receptor (AR) plays a key role in the progression of prostate cancer, and androgen-deprivation therapy (ADT) is the first line of treatment against advanced metastatic prostate cancer after surgery of the primary site [1]. The gene discussed is AR; the disease is prostate carcinoma.